DECRYPTION – The Paris Saclay Cancer Cluster will benefit from 80 to 100 million euros from the government and 150 million from Sanofi.
Five new drugs or medical devices against cancer invented in France by 2027: this is the bet of the Paris Saclay Cancer Cluster (PSCC), launched a year ago by Gustave Roussy, Sanofi, Inserm, Polytechnic Institute and Paris-Saclay University. This project – which is anchored in Villejuif where Gustave Roussy is based – will receive funding of 80 to 100 million euros from the State: the government made it official on Monday morning after a meeting on the strategy decade of the fight against cancer. The PSCC is thus the first winner of a call for expressions of interest launched by Emmanuel Macron as part of the “France 2030” plan.
The ambition was to identify “poles of excellence on a global scale bringing together companies, care, research and breakthrough innovation, [avec] for the ambition of transforming the landscape of French biomedical research”. With 1.3 million deaths each year in Europe (+25% expected by 2035), cancer is one of the…
This article is for subscribers only. You have 80% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
Already subscribed? Login